The Singapore-based, oncology-focused venture Aslan Pharmaceuticals Pte. Ltd., which is developing a pipeline of assets for Asia-prevalent tumor types, will float on the Taipei Exchange (TPEx) after holding an auction for the planned IPO in the middle of May.
KGI Securities is the lead underwriter for the offering, under which ASLAN expects to have paid in capital of TWD1,157m...






